World Pharma News

Syndicate content
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharm
Updated: 8 hours 9 min ago

Obesity-cancer connection discovery suggests strategies for improving immunotherapy

Fri, 06/14/2024 - 10:00
Immune system cells called macrophages play an unexpected role in the complicated connection between obesity and cancer, a Vanderbilt University Medical Center-led research team has discovered.

Obesity increases the frequency of macrophages in tumors and induces their expression of the immune checkpoint protein PD-1 - a target of cancer immunotherapies. The findings, published June 12 in the journal Nature, provide a mechanistic explanation for how obesity can contribute to both increased cancer risk and enhanced responses to immunotherapy.

An easier, less expensive way to power precision medicine

Thu, 06/13/2024 - 10:00
Proteins are workhorses that carry out most of the biological functions in our cells. While the genes we inherit from our parents, our so-called genome, are fixed and usually remain unchanged throughout our lives, proteins in our bodies are constantly changing, as we age, under different health conditions and upon stimulation, such as with medical treatment.

This makes monitoring proteins and their molecular changes - the study of proteomics - beneficial for drug discovery, disease diagnosis and health management.

Preparing for a world where Alzheimer's disease is treatable

Wed, 06/12/2024 - 10:00
Drugs with the potential to change the course of Alzheimer’s disease are expected to be approved by mid-year in the UK. Healthcare services may need to change to ensure that all patients have equitable access to these new modifying anti-amyloid therapies, according to research led by Queen Mary University of London and University College London (UCL).

Alzheimer's disease is the most common cause of dementia. Of the 944,000 people living with dementia in the UK, 60-80% have Alzheimer's.

Protein study could help researchers develop new antibiotics

Tue, 06/11/2024 - 10:00
A bacterial enzyme called histidine kinase is a promising target for new classes of antibiotics. However, it has been difficult to develop drugs that target this enzyme, because it is a "hydrophobic" protein that loses its structure once removed from its normal location in the cell membrane.

Now, an MIT-led team has found a way to make the enzyme water-soluble, which could make it possible to rapidly screen potential drugs that might interfere with its functions.

Treating rare skin diseases by transplanting healthy skin

Mon, 06/10/2024 - 10:00
Researchers from Nagoya University Graduate School of Medicine in Japan have successfully treated the skin diseases epidermolytic ichthyosis (EI) and ichthyosis with confetti (IWC) by transplanting genetically healthy skin to inflamed areas. Transplanting healthy skin to inflamed areas has been used as a treatment option for severe burn injuries. They applied this technique from a common disease to rare diseases.

UBC-developed oral insulin drops offer relief for diabetes patients

Fri, 06/07/2024 - 10:00
Diabetes rates continue to rise, with 11.7 million Canadians living with diabetes or pre-diabetes. At UBC, scientists have created a pain-free drug delivery method to help people with diabetes manage the disease and maintain their health more easily.

Researchers at the Li Lab have developed oral insulin drops that when placed under the tongue are quickly and efficiently absorbed by the body, potentially replacing the need for insulin injections.

GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies

Thu, 06/06/2024 - 10:00
GSK plc (LSE/NYSE: GSK) today announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million).

Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.

Protein discovery could help prevent cancer treatment-related heart damage

Wed, 06/05/2024 - 10:00
Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University. Importantly, the researchers also found that inhibiting CDK7 could help enhance the medication's cancer-killing capability.

Based on an animal model, the study findings could provide a foundation for future treatment strategies to reduce chemotherapy-related heart toxicity and increase treatment effectiveness.

The future of drug testing: Vascularized organ-on-a-chip technologies

Tue, 06/04/2024 - 10:00
In an era marked by rapid technological advancement in biomedical engineering, a groundbreaking development is set to revolutionize our approach to drug testing and disease modeling. Researchers from Shanghai University and the University of California Los Angeles have made significant strides in the field of in vitro vascularized organ-on-a-chip systems, offering a promising alternative to traditional methods that rely heavily on animal testing and simplistic two-dimensional cell cultures.

Two-Pronged Attack Strategy Boosts Immunotherapy in Preclinical Studies

Mon, 06/03/2024 - 10:00
A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack against solid tumors to boost the immune system’s ability to target and eliminate cancer cells.​​​​​​

The research focuses on an immunotherapy called adoptive cell transfer (ACT), which involves extracting T cells from a patient, enhancing their ability to fight cancer, expanding them in culture and reinfusing them into the patient's body.

Pfizer's LORBRENA® CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression

Fri, 05/31/2024 - 10:00
Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Thu, 05/30/2024 - 10:00
Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today that BlueRock's investigational cell therapy bemdaneprocel for the treatment of Parkinson's disease has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA).

Intermittent fasting shows promise in improving gut health, weight management

Wed, 05/29/2024 - 10:00
A new study by researchers from Arizona State University and their colleagues highlights a dietary strategy for significant health improvement and weight management.

Participants following an intermittent fasting and protein-pacing regimen, which involves evenly spaced protein intake throughout the day, saw better gut health, weight loss and metabolic responses. These benefits were notably greater than those seen with simple calorie restriction.

New therapy proven effective against rejection in kidney transplantation

Tue, 05/28/2024 - 10:00
Antibody-mediated rejection (AMR) is one of the most common causes of kidney transplant failure. To date, however, no treatment has proven effective in combating this complication in the long term. As part of an international and multidisciplinary clinical study led by Georg Böhmig and Katharina Mayer, Clinical Division of Nephrology and Dialysis, Department of Medicine III at MedUni Vienna and University Hospital Vienna, a new therapeutic principle in transplant medicine has been found to be both safe and highly effective.

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Mon, 05/27/2024 - 10:00
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.

Young people are increasingly using Wegovy and Ozempic

Fri, 05/24/2024 - 10:00
Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States are surprisingly scarce.

Now, a national study from Michigan Medicine shows that the use of these weight loss drugs is increasing rapidly in adolescents and young adults 12-25 years, especially females.

Regular fish oil supplement use might boost first time heart disease and stroke risk

Thu, 05/23/2024 - 10:00
Regular use of fish oil supplements might increase, rather than lessen, the risk of first time heart disease and stroke among those in good cardiovascular health, but may slow progression of existing poor cardiovascular health and lower the risk of death, suggest the results of a large long term study, published in the open access journal BMJ Medicine.

Fish oil is a rich source of omega 3 fatty acids, and as such, is recommended as a dietary preventive to ward off the development of cardiovascular disease.

Scientists create tailored drug for aggressive breast cancer

Wed, 05/22/2024 - 10:00
Scientists have used breast cancer cells' weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumours.

The research, published today in Clinical Cancer Research by a team from King's College London and funded by Breast Cancer Now, marks a new method in cancer treatment.

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030

Tue, 05/21/2024 - 10:00
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade. To drive sustained growth beyond 2030, the Company will continue investing in transformative new technologies and platforms that will shape the future of medicine.

Clinicians report success with first test of drug in a patient with life-threatening blood clotting disorder

Mon, 05/20/2024 - 10:00
A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic thrombocytopenic purpura (iTTP), a rare disorder characterized by uncontrolled clotting throughout the small blood vessels. The group describes the first clinical use of the drug for iTTP in the New England Journal of Medicine.